Skip to main content
Article thumbnail
Location of Repository

Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke

By Lian Zhao, Laura J. Gray, Jo Leonardi-Bee, Chris Weaver, Stan Heptinstall and Philip M.W. Bath
Year: 2006
OAI identifier: oai:eprints.nottingham.ac.uk:433
Provided by: Nottingham ePrints

Suggested articles

Citations

  1. (2004). A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and Creactive protein following myocardial infarction: the CADET trial. J Thromb Haemost doi
  2. (1984). Acceleration of thrombin antithrombin complex formation in rat hindquartes via heparin-like molecules bound to the endothelium.
  3. (1989). An improved chemiluminescence assay suggests non nitric oxide mediated action of lysophoshatidylcholine and acetylcholine. Proc Soc Exp Biol Med
  4. (2002). Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ
  5. (2003). C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis. Circulation doi
  6. (2002). Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
  7. (1999). Chemokines and atherosclerosis. Atherosclerosis
  8. (1993). Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke
  9. (2003). Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke
  10. (1991). Dipyridamole potentiates the antiaggregating and vasodilator activity of nitric oxide.
  11. (2000). Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells. Circulation
  12. (2005). E, and Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a metaanalysis of individual patient data from randomized controlled trials. Stroke
  13. (2004). Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. doi
  14. (2000). Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis doi
  15. (2005). Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and lecocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost doi
  16. (2001). Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
  17. (1986). Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium. doi
  18. (2001). Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol doi
  19. (2001). Effects of low-dose aspirin on serum Creactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. doi
  20. (1983). Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature doi
  21. (1982). Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.
  22. (2001). Inflammation and Thrombosis: The Clot Thickens. Circulation
  23. (2004). Inflammation as a cardiovascular risk factor. Circulation
  24. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev
  25. (2001). Near-field amplification of antithrombotic effects of dipyridamole through vessel walls cells. Neurology
  26. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. doi
  27. (1998). p-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets
  28. (1989). PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood
  29. (2003). Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome. doi
  30. (2003). Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications. doi
  31. (1993). Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb
  32. (2004). Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int
  33. (1980). Platelet release reaction in vivo in patients with ischaemic heart disease after isometric exercise and its prevention with dipyridamole. Thromb Haemost
  34. (2000). Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood
  35. (1994). Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sci
  36. (2000). Role of von Willebrand factor in platelet thrombus formation. Ann Med doi
  37. (2004). Soluble CD40 ligand and platelets: selfperpetuating pathogenic loop in thrombosis and inflammation?
  38. (2002). Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis
  39. (1995). von Willebrand factor, soluble Pselectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.